Polyvalent DNA Vaccines Expressing HA Antigens of H5N1 Influenza Viruses with an Optimized Leader Sequence Elicit Cross-Protective Antibody Responses

• Shixia Wang,

  Affiliations China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• Anthony Hackett,

  Affiliation Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• Na Jia,

  Affiliation Beijing Institute of Microbiology and Epidemiology, and State Key Laboratory of Pathogen and Biosecurity, Beijing, China

  ⨯
• Chunhua Zhang,

  Affiliations Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  ⨯
• Lu Zhang,

  Affiliations Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  ⨯
• Chris Parker,

  Affiliation Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• An Zhou,

  Affiliation Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• Jun Li,

  Affiliations Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  ⨯
• Wu-Chun Cao,

  Affiliation Beijing Institute of Microbiology and Epidemiology, and State Key Laboratory of Pathogen and Biosecurity, Beijing, China

  ⨯
• Zuhu Huang,

  Affiliations Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  ⨯
• Yan Li,

  Affiliation National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

  ⨯
• Shan Lu

  * E-mail: shan.lu@umassmed.edu

  Affiliations Jiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯